Kronos stops work on leukemia drug; Aldeyra shares rally on eczema data; Atavistik Bio's $40M
Kronos Bio stops blood cancer program: The biotech on Monday said Phase Ib data of lanraplenib in a mutated subset of …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
